Page 243 - Read Online
P. 243

D'Angelo et al. J Cancer Metastasis Treat 2019;5:30  I  http://dx.doi.org/10.20517/2394-4722.2018.86                      Page 3 of 18

                  Survival                                                       28   months  2 year




                  Palliation    Radiotherapy,   brachytherapy,   stenting or   dilatation  Endoscopic   hemostatic   procedures, stents  Endoluminal   stent, endoscopic   or endovascular   therapy for   bleeding





                  Surgery  Only for   complications,   obstruction or   bleeding  Only for   emergency   situation,   bypass for   obstruction  Obstruction,   bleeding  obstruction,   mass effect  Emergency,   bypass for   obstruction  Obstruction,   bleeding  Bypass for   obstruction  Intestinal   obstruction,   bleeding,   perforation





                  Therapy  Chemotherapy or   endocrine therapy  Systemic therapy,   hormonal therapy  Systemic therapy   Systemic therapy,   radiotherapy,   endoscopy  Systemic therapy,   hormonal therapy  Systemic therapy  Systemic therapy  Systemic therapy  Individualized,   systemic therapy  Medical therapy


                  Gastric metastasis   receptor  Positive CK7,   GCDFP-15, CEA, ER,   PgR. Negative CK20  Positive CK,   GCDFP-15, CEA, ER,   PgR. Negative CK20  Positive ER, PgR,   CK7, CK18. Negative   HER2, CK20  ER, PgR, E-cadherin,








                  Gastric   histology  Signet ring   morphology  Signet ring   morphology  Signet ring  Signet ring  Signet ring


                  Gastric   biopsy  Negative   in 30%                                            Negative   in 50%



                  Breast   histology  Lobular   83%  Lobular   Lobular  Lobular  Lobular  Lobular   83%  Lobular  Lobular

                                Thickened   visceral   wall, other   metastasis  has low   sensitivity

                  CT                                                                                      ER: estrogen receptor; PgR: progesterone receptor; HER: human epithelial receptor; CK: cytokeratin; GCDFP-15: gross cystic disease fluid protein 15; CEA: carcinoembryonic antigen


                  Endoscopy  Linitis plastica,   negative in 50%  Linitis plastica,   normal mucosa in   30%  Diffuse infiltration  Linitis plastica  Normal in 50%  3 patterns: localized,  PET   diffuse, external   compression*  Sub-mucosal type   lesion, solitary   lesions*  Linitis plastica  Linitis plastica,   normal mucosa in   50%  Discrete nodules,   linitis plastica  Linitis plastica   (lobular type);   discrete nodules   (ductal type)





                      Non specific: dysphagia,   dyspepsia, anorexia,  abdominal pain, early satiety,  nausea, vomiting, bleeding  Non specific: nausea,  vomiting, epigastric pain,  anorexia, dyspepsia, bloating  Inexpressive  Nausea, vomiting, epigastric   pain, anorexia, weight   loss, dysphagia, melena,  hematemesis, iron deficiency  anemia, guaiac positive stools  Epigastric pain, melena,  anemia, nausea, vomiting  Epigastric pain, dysphagia,  vomiting, gastrointestin



                  Symptoms
               Table 1. Summary of reviews from 2000 to 2018  DFS  Incidence  Study  Many  0.3%-18% Pectasides et al. [7] ,   years  2009  Few  7.4%-18% Ayantude et al. [8] ,   months   2007  to several   years  4-5 years  2%-18% Villa Guzman et al. [9] ,   2017  6%-18% Reiman et al. [10] ,   2001  7 years  8%-35% Critchley et al. [11] ,   2011  50-78  Namikawa et al. [13] ,   months  2013  75.6  Weigt et al. [12] , 2015  months  2%-18% Barranco et al. [14] ,   2017  Many
   238   239   240   241   242   243   244   245   246   247   248